Annual General Meeting held on May 12, 2026 - Poll Results

Hong Kong, Shanghai, & Florham Park, NJ: Tuesday, May 12, 2026: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX:13) today announces that all ordinary resolutions and special resolution put to its Annual General Meeting ("AGM") held on May 12, 2026 were duly passed. The poll results of the resolutions were as follows:

*  Percentages rounded to 4 decimal places.

^# A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for or against a resolution.

^ The full text of Resolutions 4, 5 and 6 are set out in the notice of AGM dated April 10, 2026.

Notes:

(1)       Except for Ms Ling YANG and Professor MOK Shu Kam, Tony who had prior overseas work commitments and were unable to attend the AGM, all Directors of the Company, namely Dr Dan ELDAR, Dr Weiguo SU, Mr CHENG Chig Fung, Johnny, Ms Edith SHIH, Dr Renu BHATIA, Dr Chaohong HU, Professor TAN Shao Weng, Daniel and Mr WONG Tak Wai, attended the AGM, either in person or by means of electronic facilities.

(2)       Number of shares entitling the holders to attend and vote on the resolution at the AGM: 872,335,120 shares, being the total number of issued shares of the Company.  The Company did not hold any treasury shares (including any treasury shares held or deposited with Central Clearing and Settlement System) as at the AGM date.

(3)       Number of shares entitling the holders to attend and abstain from voting in favor as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ¡§Listing Rules¡¨) at the AGM: Nil.

(4)       Number of shares for holders required under the Listing Rules to abstain from voting at the AGM: Nil.

(5)       The scrutineer for the poll at the AGM was Computershare Investor Services (Jersey) Limited, the Principal Share Registrar of the Company.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. Іt is committed to the discovery, global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, and the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.

CONTACTS